PDF herunterladen
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2022; 43(01): 029-033
DOI: 10.1055/s-0042-1742653
Mini-Review Article

Pulmonary Oncology—Scope of the Pulmonologist

Sandeep Tandon 
1   Department of Pulmonary Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Pavankumar Biraris
1   Department of Pulmonary Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
,
Maheema Bhaskar
1   Department of Pulmonary Medicine, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

The International Agency for Research on Cancer GLOBOCAN project has predicted that India's cancer burden will nearly double in the next 20 years, from slightly more than a million new cases in 2012 to more than 1·7 million by 2035. In India, chronic respiratory diseases have emerged as a leading health care burden with chronic obstructive pulmonary disease (COPD) being the second leading cause of deaths and disability-adjusted life years. Patients with COPD are 6.35 times more likely to develop lung cancer. The deadly dual epidemic of “chronic respiratory diseases and cancer” warrants not only prevention but also creating an increased awareness among oncologists as well as pulmonologists to enable early diagnosis and treatment. It would be incorrect to assume that the scope of a pulmonologist in oncology is just diagnosing and treating lung cancer or prescribing chemotherapy for lung cancer. There is a larger world full of opportunities beyond that, and we look at the pulmonologist as a member of a multidisciplinary oncology team working together with the surgical, radiation, and medical oncologist and ancillary specialties to address all the issues highlighted earlier that are faced in oncology practice. The current exposure to pulmonary oncology and related complications during postgraduate training for respiratory medicine in India is limited. It is necessary not only to educate the pulmonologist on their role in an oncology setup but also to increase the awareness across all oncology specialties regarding the pulmonologist's contribution in management of the cancer patient. In this review, written based on our experience gained in our pulmonology service in our tertiary oncology center, we have tried to portray the wide role of the pulmonologist in oncology. We have realized that what is lacking is the basic awareness regarding the above potential, both among pulmonologists and oncologists. Our mission is to take this message across specialists in India, highlighting how we can work synergistically in the fight against cancer.

Keywords

pulmonology - pulmonary oncology - pulmonologist - thoracic oncology


Publikationsverlauf

Artikel online veröffentlicht:
21. Februar 2022

© 2022. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
    CrossrefPubMedGoogle Scholar
  • 2 India State-Level Disease Burden Initiative CRD Collaborators. The burden of chronic respiratory diseases and their heterogeneity across the states of India: the Global Burden of Disease Study 1990-2016. Lancet Glob Health 2018; 6 (12) e1363-e1374
    CrossrefPubMedGoogle Scholar
  • 3 India State-Level Disease Burden Initiative Cancer Collaborators. The burden of cancers and their variations across the states of India: the Global Burden of Disease Study 1990-2016. [published correction appears in Lancet Oncol 2018 Oct 3;] Lancet Oncol 2018; 19 (10) 1289-1306
    CrossrefPubMedGoogle Scholar
  • 4 Noronha V, Tsomo U, Jamshed A. et al. A fresh look at oncology facts on south central Asia and SAARC countries. South Asian J Cancer 2012; 1 (01) 1-4
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 5 Mathew A. Global survey of clinical oncology workforce. J Glob Oncol 2018; 4: 1-12
    Google Scholar
  • 6 Søgaard M, Thomsen RW, Bossen KS, Sørensen HT, Nørgaard M. The impact of comorbidity on cancer survival: a review. Clin Epidemiol 2013; 5 (Suppl. 01) 3-29
    CrossrefPubMedGoogle Scholar
  • 7 Gottlieb M, Marsaa K, Godtfredsen NS, Mellemgaard A. Prevalence and management of pulmonary comorbidity in patients with lung and head and neck cancer. Acta Oncol 2015; 54 (05) 767-771
    CrossrefPubMedGoogle Scholar
  • 8 Mohan A, Mohan C, Pathak AK, Pandey RM, Guleria R. Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer. Respirology 2007; 12 (02) 240-247
    CrossrefPubMedGoogle Scholar
  • 9 Brenner DR, McLaughlin JR, Hung RJ. Previous lung diseases and lung cancer risk: a systematic review and meta-analysis. PLoS One 2011; 6 (03) e17479
    CrossrefPubMedGoogle Scholar
  • 10 Le Jeune I, Gribbin J, West J, Smith C, Cullinan P, Hubbard R. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med 2007; 101 (12) 2534-2540
    CrossrefPubMedGoogle Scholar
  • 11 Hubbard R, Venn A, Lewis S, Britton J. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am J Respir Crit Care Med 2000; 161 (01) 5-8
    CrossrefPubMedGoogle Scholar
  • 12 Harris JM, Johnston ID, Rudd R, Taylor AJ, Cullinan P. Cryptogenic fibrosing alveolitis and lung cancer: the BTS study. Thorax 2010; 65 (01) 70-76
    CrossrefPubMedGoogle Scholar
  • 13 Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35 (07) 496-499
    CrossrefPubMedGoogle Scholar
  • 14 Chiyo M, Sekine Y, Iwata T. et al. Impact of interstitial lung disease on surgical morbidity and mortality for lung cancer: analyses of short-term and long-term outcomes. J Thorac Cardiovasc Surg 2003; 126 (04) 1141-1146
    CrossrefPubMedGoogle Scholar
  • 15 Miyazaki K, Satoh H, Kurishima K. et al. Impact of interstitial lung disease on survival for patients with non-small cell lung cancer. Anticancer Res 2009; 29 (07) 2671-2674
    Google Scholar
  • 16 Kumar P, Goldstraw P, Yamada K. et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg 2003; 125 (06) 1321-1327
    CrossrefPubMedGoogle Scholar
  • 17 Park J, Kim DS, Shim TS. et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001; 17 (06) 1216-1219
    CrossrefPubMedGoogle Scholar
  • 18 Chida M, Kobayashi S, Karube Y. et al. Incidence of acute exacerbation of interstitial pneumonia in operated lung cancer: institutional report and review. Ann Thorac Cardiovasc Surg 2012; 18 (04) 314-317
    CrossrefPubMedGoogle Scholar
  • 19 Chida M, Ono S, Hoshikawa Y, Kondo T. Subclinical idiopathic pulmonary fibrosis is also a risk factor of postoperative acute respiratory distress syndrome following thoracic surgery. Eur J Cardiothorac Surg 2008; 34 (04) 878-881
    CrossrefPubMedGoogle Scholar
  • 20 Sato T, Teramukai S, Kondo H. et al; Japanese Association for Chest Surgery. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 2014; 147 (05) 1604-1611.e3
    CrossrefPubMedGoogle Scholar
  • 21 Fujimoto T, Okazaki T, Matsukura T. et al. Operation for lung cancer in patients with idiopathic pulmonary fibrosis: surgical contraindication?. Ann Thorac Surg 2003; 76 (05) 1674-1678 , discussion 1679
    CrossrefPubMedGoogle Scholar
  • 22 Voltolini L, Bongiolatti S, Luzzi L. et al. Impact of interstitial lung disease on short-term and long-term survival of patients undergoing surgery for non-small-cell lung cancer: analysis of risk factors. Eur J Cardiothorac Surg 2013; 43 (01) e17-e23
    CrossrefPubMedGoogle Scholar
  • 23 Watanabe A, Higami T, Ohori S, Koyanagi T, Nakashima S, Mawatari T. Is lung cancer resection indicated in patients with idiopathic pulmonary fibrosis?. J Thorac Cardiovasc Surg 2008; 136 (05) 1357-1363 , 1363.e1–1363.e2
    CrossrefPubMedGoogle Scholar
  • 24 Macmillan Cancer Support, Royal College of Anaesthetists. National Institute of Health Research - Prehabilitation for people with Cancer
    Google Scholar
  • 25 Simonsen DF, Farkas DK, Horsburgh CR, Thomsen RW, Sørensen HT. Increased risk of active tuberculosis after cancer diagnosis. J Infect 2017; 74 (06) 590-598
    CrossrefPubMedGoogle Scholar
  • 26 Engels EA, Shen M, Chapman RS. et al. Tuberculosis and subsequent risk of lung cancer in Xuanwei, China. Int J Cancer 2009; 124 (05) 1183-1187
    CrossrefPubMedGoogle Scholar
  • 27 Dobler CC, Cheung K, Nguyen J, Martin A. Risk of tuberculosis in patients with solid cancers and haematological malignancies: a systematic review and meta-analysis. Eur Respir J 2017; 50 (02) 1700157
    CrossrefPubMedGoogle Scholar
  • 28 Wu CY, Hu HY, Pu CY. et al. Aerodigestive tract, lung and haematological cancers are risk factors for tuberculosis: an 8-year population-based study. Int J Tuberc Lung Dis 2011; 15 (01) 125-130
    PubMedGoogle Scholar